一项最新的间接治疗对比研究表明,礼来旗下Zepbound(替尔泊肽10毫克和15毫克)在减重方面表现优于Wegovy HD(司美格鲁肽注射液7.2毫克)。
一项最新的间接治疗对比研究表明,礼来旗下Zepbound(替尔泊肽10毫克和15毫克)在减重方面表现优于Wegovy HD(司美格鲁肽注射液7.2毫克)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.